Targovax ASA appoints Dr. Erik Digman Wiklund as new CEO
Oslo, Norway, 20 October 2021 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces the appointment of Dr. Erik Digman Wiklund as Chief Executive Officer (CEO). Dr. Wiklund has intimate knowledge of the company and its technology having served as Chief Business Officer (CBO) and Chief Financial Officer (CFO) of Targovax since 2017.Dr. Erik Digman Wiklund said: “I am very excited to be entrusted with the opportunity to lead Targovax into the next stage of development. The ONCOS-102 program has